Study of E7389 in Patients With Advanced Solid Tumors

Phase 1

Completed

• Conditions: Advanced Solid Tumors
• Interventions: Drug: E7389

• Registration Number: NCT00069264
• Lead Sponsor: Eisai Inc.

Brief Summary

To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-09
• Study First Submitted: 2003-09-19
• Study First Submitted QC: 2003-09-23
• Study First Posted: 2003-09-24
• Primary Completion: 2005-03
• Study Completion: 2005-07
• Status Verified: 2011-11
• Results First Submitted: 2011-11-16
• Results First Submitted QC: 2011-11-16
• Last Update Submitted: 2011-11-16
• Results First Posted: 2011-12-20
• Last Update Posted: 2011-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
E7389	E7389	-

Primary Outcome Measures

Name	Time	Method
Determination of the Maximum Tolerated Dose	28 Days